WTX-921 / Werewolf Therap - LARVOL DELTA

Development of WTX-921 a conditionally activated IL-10 INDUKINETM molecule for the treatment of Inflammatory Bowel Disease (IMMUNOLOGY 2025) - "Multi-immunofluorescence spatial imaging shows greatly reduced CD45+ cells, including CD4+ effector T cells and myeloid cells in colons from animals treated with WTX-921. Together, these data support the continued development of WTX-921, an IL-10 INDUKINE molecule, for the treatment of IBD.Keywords: Diseases Autoimmunity; Molecules Cytokines; Processes Inflammation; Tissues Mucosa"

Anemia • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Thrombocytopenia • Ulcerative Colitis • IL10 • PTPRC

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) - "New results also highlight WTX-921’s effective masking of IL-10 via its optimized IL-10 blocking domain, which prevents the peripheral off-tissue pharmacodynamic effects of IL-10....WTX-921 treatment demonstrated efficacy in the ACT animal model of colitis over a duration of 4 weeks, preventing weight loss and resulting in reduced Disease Activity Index (DAI) scores. WTX-921 also inhibited inflammation, evidenced by a decrease in the infiltration/expansion of immune cells (including CD4+ effector T cells and myeloid cells) and reduced RNA levels of inflammatory cytokines within the colon of treated animals."

Preclinical • Inflammatory Bowel Disease

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook (GlobeNewswire) - "Preclinical Portfolio: includes development candidate...WTX-921, an IL-10 INDUKINE molecule for treatment of inflammatory bowel disease (IBD) and potentially other inflammatory diseases. In 2025, Werewolf plans to complete ongoing pre-clinical work to support IND-stage programs and seek strategic partnerships to advance these programs."

Preclinical • Immunology • Inflammation • Inflammatory Bowel Disease

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases (GlobeNewswire) - "Werewolf Therapeutics....announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflammatory diseases, to the Company’s pipeline. This pipeline expansion underscores the transformative promise of the Werewolf’s PREDATOR platform to apply the INDUKINE approach to therapeutic areas outside of oncology....To address IBD, Werewolf leveraged this unique drug design approach and identified the optimal cytokine masking and disease selective linkers for delivery of IL-10 to inflammatory disease tissue, in this case the colon."

New molecule • Immunology • Inflammation • Inflammatory Bowel Disease

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting (GlobeNewswire) - "Werewolf Therapeutics...announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models...at IMMUNOLOGY 2024, the annual meeting of the American Association of Immunologists (AAI)....Key takeaways are that Werewolf’s IL-10 INDUKINE molecules: Contain human IL-10, a blocking domain, and a half-life extension domain tethered together by proprietary protease-sensitive linkers that are cleaved by UC and Crohn’s human colon samples; Are peripherally inactive and conditionally active in the inflamed colon, where the IL-10 is released locally due to cleavage of the linkers in the dysregulated protease milieu..."

Preclinical • Crohn's disease • Ulcerative Colitis

Development of conditionally active IL-10 INDUKINETM molecules for the treatment of inflammatory bowel disease (IMMUNOLOGY 2024) - "In a mouse model of colitis, IL-10 INDUKINE molecules prevent weight loss, intestinal damage and inhibit inflammatory cytokine production within the colon. Together these data support the potential of an IL-10 INDUKINE molecule for the treatment of IBD."

Late-breaking abstract • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL10

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR Platform in Immunology-Based Diseases at AAI Annual Meeting (GlobeNewswire) - "Werewolf Therapeutics, Inc...announced the publication of an abstract for an upcoming poster presentation at IMMUNOLOGY 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois."

Clinical data • Immunology • Inflammatory Bowel Disease